Baseline Laboratory Testing Before Starting Risperidone
Before initiating risperidone, obtain comprehensive metabolic monitoring including fasting glucose, lipid panel, liver function tests, complete blood count, renal function tests, prolactin level, electrocardiogram, and baseline weight/BMI measurements. 1, 2
Essential Baseline Laboratory Tests
Metabolic Parameters (Critical Priority)
- Fasting glucose or HbA1c: Risperidone increases risk of hyperglycemia and diabetes mellitus, with metabolic effects intermediate between low-risk agents (aripiprazole, ziprasidone) and high-risk agents (olanzapine, clozapine). 3, 2
- Fasting lipid panel (total cholesterol, triglycerides, LDL, HDL): Risperidone causes dyslipidemia with mean increases in cholesterol of 6.9 mg/dL and variable triglyceride changes in clinical trials. 2, 4
- Body Mass Index (BMI) and waist circumference: Document baseline weight as risperidone causes significant weight gain, particularly in children and adolescents. 1, 5, 2
- Blood pressure: Establish baseline due to risk of orthostatic hypotension and long-term cardiovascular effects. 1, 5
Hepatic Function
- Liver function tests (ALT, AST, alkaline phosphatase, bilirubin): Risperidone can cause transient hepatic transaminase elevations and, rarely, hepatotoxicity. This is particularly important as case reports document acute cholestatic hepatitis and hepatocellular damage with risperidone. 6, 7, 8, 9
Hematologic Testing
- Complete blood count with differential: While agranulocytosis is primarily associated with clozapine, leukocytopenia has been reported with risperidone in adolescents. 6
Renal Function
- Blood urea nitrogen, creatinine, and electrolytes: Establish baseline renal function for ongoing monitoring. 5, 6, 5
Cardiac Assessment
- Electrocardiogram (ECG): Risperidone may cause QT prolongation, making baseline ECG essential to identify pre-existing cardiac abnormalities. 6, 1
Endocrine Testing
- Prolactin level: Risperidone significantly elevates prolactin levels (can exceed 200 mg/liter), which may cause galactorrhea, menstrual irregularities, and sexual dysfunction. 10, 1
- Pregnancy test in females of childbearing age: Document pregnancy status before initiating treatment. 5
Follow-Up Monitoring Schedule
Intensive Early Monitoring Phase
- Fasting glucose: Recheck at 4 weeks after initiation, then at 12-16 weeks. 3, 2
- Weight and BMI: Monitor weekly for 6 weeks, then monthly for 3 months. 1, 5
- Blood pressure: Check weekly for 6 weeks. 1, 5
Ongoing Maintenance Monitoring
- Quarterly assessments (first 3 months): Fasting glucose, lipid panel, blood pressure. 1, 5
- Annual monitoring thereafter: Complete metabolic panel including glucose, lipids, liver function tests, renal function, prolactin, and ECG. 1, 3
Special Populations
Children and Adolescents
The same comprehensive baseline testing applies, with particular attention to growth parameters and pubertal development, as risperidone may affect sexual maturation. 6, 5, 8
Patients with Pre-existing Diabetes
Those with established diabetes require more frequent glucose monitoring to detect worsening glycemic control early. 2
Common Pitfalls to Avoid
- Do not rely on random glucose alone: If fasting samples cannot be obtained initially, use random glucose for screening but prioritize obtaining fasting measurements if abnormal. 1
- Do not skip liver function tests: Despite being less emphasized than metabolic monitoring, hepatotoxicity can occur rapidly (within 3 weeks) and requires baseline documentation. 7, 8, 9
- Do not forget prolactin monitoring: Risperidone causes more prolactin elevation than other atypical antipsychotics except paliperidone, making baseline measurement essential for comparison if symptoms develop. 10